YM155 inhibits topoisomerase function.

Anticancer Drugs

aCancer Center, Georgia Regents University Cancer Center bDepartment of Surgery cDepartment of ENT Surgery, Center for Biotechnology and Genomic Medicine dDepartment of Medicine, Medical College of Georgia, Augusta eDepartment of Chemistry, Georgia State University, Atlanta, Georgia, USA.

Published: February 2017

YM155 (sepantronium bromide) has been evaluated in clinical trials as a survivin suppressant, but despite positive signals from early work, later studies were negative. Clarification of the mechanism of action of YM155 is important for its further development. YM155 affects cells in a cell cycle-specific manner. When cells are in G1, YM155 prevented their progression through the S phase, leaving the cells at G1/S when exposed to YM155. Passage through mitosis from G2 is also defective following YM155 exposure. In this study, YM155 did not behave like a typical DNA intercalator in viscosity, circular dichroism, and absorption spectroscopy studies. In addition, molecular modeling experiments ruled out YM155 DNA interaction to produce DNA intercalation. We show that YM155 inhibited topoisomerase 2α decatenation and topoisomerase 1-mediated cleavage of DNA, suggesting that YM155 inhibits the enzyme function. Consistent with these findings, DNA double-strand break repair was also inhibited by YM155.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5225247PMC
http://dx.doi.org/10.1097/CAD.0000000000000441DOI Listing

Publication Analysis

Top Keywords

ym155
12
ym155 inhibits
8
dna
5
inhibits topoisomerase
4
topoisomerase function
4
function ym155
4
ym155 sepantronium
4
sepantronium bromide
4
bromide evaluated
4
evaluated clinical
4

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!